Clinical trials with oncolytic measles virus: Current status and future prospects

Pavlos Msaouel; Mateusz Opyrchal; Angela Dispenzieri; Kah Whye Peng; Mark J. Federspiel; Stephen J. Russell; Evanthia Galanis

doi:10.2174/1568009617666170222125035

Clinical trials with oncolytic measles virus: Current status and future prospects

Pavlos Msaouel, Mateusz Opyrchal, Angela Dispenzieri, Kah Whye Peng, Mark J. Federspiel, Stephen J. Russell, Evanthia Galanis

Research output: Contribution to journal › Review article › peer-review

50 Scopus citations

Abstract

Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.

Original language	English (US)
Pages (from-to)	177-187
Number of pages	11
Journal	Current Cancer Drug Targets
Volume	18
Issue number	2
DOIs	https://doi.org/10.2174/1568009617666170222125035
State	Published - 2018

Keywords

Cancer gene therapy
MV-CEA
MV-NIS
Measles virus clinical trials
Oncolytic measles
Virotherapy

ASJC Scopus subject areas

Oncology
Pharmacology
Drug Discovery
Cancer Research

Access to Document

10.2174/1568009617666170222125035

Cite this

@article{1435d04662c14f928299a056e72a75d3,

title = "Clinical trials with oncolytic measles virus: Current status and future prospects",

abstract = "Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.",

keywords = "Cancer gene therapy, MV-CEA, MV-NIS, Measles virus clinical trials, Oncolytic measles, Virotherapy",

author = "Pavlos Msaouel and Mateusz Opyrchal and Angela Dispenzieri and Peng, {Kah Whye} and Federspiel, {Mark J.} and Russell, {Stephen J.} and Evanthia Galanis",

note = "Publisher Copyright: {\textcopyright} 2018 Bentham Science Publishers.",

year = "2018",

doi = "10.2174/1568009617666170222125035",

language = "English (US)",

volume = "18",

pages = "177--187",

journal = "Current Cancer Drug Targets",

issn = "1568-0096",

publisher = "Bentham Science Publishers B.V.",

number = "2",

}

TY - JOUR

T1 - Clinical trials with oncolytic measles virus

T2 - Current status and future prospects

AU - Msaouel, Pavlos

AU - Opyrchal, Mateusz

AU - Dispenzieri, Angela

AU - Peng, Kah Whye

AU - Federspiel, Mark J.

AU - Russell, Stephen J.

AU - Galanis, Evanthia

PY - 2018

Y1 - 2018

N2 - Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.

AB - Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.

KW - Cancer gene therapy

KW - MV-CEA

KW - MV-NIS

KW - Measles virus clinical trials

KW - Oncolytic measles

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=85021206999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021206999&partnerID=8YFLogxK

U2 - 10.2174/1568009617666170222125035

DO - 10.2174/1568009617666170222125035

M3 - Review article

C2 - 28228086

AN - SCOPUS:85021206999

SN - 1568-0096

VL - 18

SP - 177

EP - 187

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

IS - 2

ER -

Clinical trials with oncolytic measles virus: Current status and future prospects

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this